7,580.07

-140.32

-1.82%

51,770.31

-572.29

-1.09%

25,437.00

-747.70

-2.86%

2,811.84

-47.38

-1.66%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,898.90

-132.50

-3.29%

77,826.80

+302.87

+0.39%

Crude Oil Dec 26

104.12

+2.12

+2.08%

US Private Equity

10,850.63

-82.20

-0.75%

NSE - Delayed Quote INR

Glenmark Pharmaceuticals Limited (GLENMARK.NS)

2,298.70 -40.30 (-1.72%)

At close: October 30 at 3:28:18 PM GMT+5:30

Loading Chart for GLENMARK.NS

Chart Range Bar

Interval:

In partnership with ChartIQ

Glenmark opens Allentown distribution hub in US

Glenmark opens Allentown distribution hub in US

The Bet Glenmark Holders Made

The Bet Glenmark Holders Made

Glenmark Pharmaceuticals Inaugurates U.S. Distribution Center in Allentown

Glenmark Pharmaceuticals Inaugurates U.S. Distribution Center in Allentown

Glenmark Pharmaceuticals and South Piedmont Community College Launch Aseptic Training Facility in Monroe, N.C.

Glenmark Pharmaceuticals and South Piedmont Community College Launch Aseptic Training Facility in Monroe, N.C.

Glenmark Pharmaceuticals Ltd (BOM:532296) Q4 2026 Earnings Call Highlights: Strong Revenue ...

Glenmark Pharmaceuticals Ltd (BOM:532296) Q4 2026 Earnings Call Highlights: Strong Revenue ...

Glenmark Pharmaceuticals Receives U.S. FDA Approval for Progesterone Vaginal Inserts, 100 mg

Glenmark Pharmaceuticals Receives U.S. FDA Approval for Progesterone Vaginal Inserts, 100 mg

Glenmark Pharmaceuticals Announces Strategic Shift to Direct Commercialization and Distribution of RYALTRIS® in the U.S., Significantly Expanding Its Innovative Portfolio

Glenmark Pharmaceuticals Announces Strategic Shift to Direct Commercialization and Distribution of RYALTRIS® in the U.S., Significantly Expanding Its Innovative Portfolio

Cosmo and Glenmark Announce Market Authorisation of Winlevi® (clascoterone) 10 mg/g cream for Treatment of Acne in 17 countries in Europe

Cosmo and Glenmark Announce Market Authorisation of Winlevi® (clascoterone) 10 mg/g cream for Treatment of Acne in 17 countries in Europe

Cosmo Welcomes the Launch of Winlevi(R) in Key European Markets by Its Partner Glenmark

Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials

Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials

Oligometastatic Disease Market Analysis Report 2026-2036, Profiles of Leading Players - Dompe Farmaceutici, Bausch Health, Merck, Pfizer, and Glenmark Pharmaceuticals

Oligometastatic Disease Market Analysis Report 2026-2036, Profiles of Leading Players - Dompe Farmaceutici, Bausch Health, Merck, Pfizer, and Glenmark Pharmaceuticals

Mobilize your Website

View Site in Mobile | Classic

Share by: